Quest Diagnostics' Haystack MRD Test Gains New York Approval, Enhancing Cancer Detection

Quest Diagnostics’ Haystack MRD Test Gains New York Approval, Enhancing Cancer Detection

On June 24, 2026, Quest Diagnostics announced that its Haystack MRD® test received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This approval allows the company to offer its circulating tumor DNA (ctDNA) liquid biopsy test for detecting minimal residual disease (MRD) in patients with solid tumor cancers across all 50 U.S. states.

Significance of the Approval

New York’s CLEP maintains stringent standards for laboratory-developed tests, requiring thorough technical review and approval before patient testing. Achieving this approval underscores the reliability and accuracy of Quest Diagnostics’ Haystack MRD test, potentially enhancing early detection and monitoring of cancer recurrence.

Impact on Quest Diagnostics’ Stock Performance

Following the announcement, Quest Diagnostics’ stock (NYSE: DGX) experienced a slight decline, closing at $207.44 on July 10, 2026, down 0.39% from the previous close. This movement reflects typical market fluctuations and investor responses to new developments.

Broader Implications for the Healthcare Diagnostic Sector

The approval of the Haystack MRD test highlights the growing importance of advanced diagnostic tools in oncology. As healthcare providers increasingly adopt liquid biopsy tests for their non-invasive nature and effectiveness, companies like Quest Diagnostics are well-positioned to meet this demand, potentially influencing the competitive landscape of the diagnostic information services industry.

Conclusion

Quest Diagnostics’ recent approval for its Haystack MRD test in New York represents a significant advancement in cancer diagnostics. While the immediate stock market response was modest, the long-term implications for patient care and the company’s market position are substantial. Investors and stakeholders should monitor how this development influences Quest Diagnostics’ performance and the broader healthcare diagnostic sector.